메뉴 건너뛰기




Volumn 38, Issue 10, 2016, Pages 2265-2276

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Author keywords

electrolytes; natriuresis; pharmacodynamics

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BICARBONATE; CHLORIDE; EMPAGLIFLOZIN; GLUCOSE; METFORMIN; RENIN; SODIUM; UREA; URIC ACID; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 84994268329     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.09.001     Document Type: Article
Times cited : (70)

References (26)
  • 1
    • 83655184724 scopus 로고    scopus 로고
    • Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
    • 1 Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 83-90
    • Grempler, R.1    Thomas, L.2    Eckhardt, M.3
  • 2
    • 76249133903 scopus 로고    scopus 로고
    • Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
    • 2 Gerich, J.E., Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27 (2010), 136–142.
    • (2010) Diabet Med , vol.27 , pp. 136-142
    • Gerich, J.E.1
  • 3
    • 65349196064 scopus 로고    scopus 로고
    • Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes
    • 3 List, J.F., Woo, V., Morales, E., et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32 (2009), 650–657.
    • (2009) Diabetes Care , vol.32 , pp. 650-657
    • List, J.F.1    Woo, V.2    Morales, E.3
  • 4
    • 84864283226 scopus 로고    scopus 로고
    • SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
    • 4 Ferrannini, E., Solini, A., SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8 (2012), 495–502.
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 495-502
    • Ferrannini, E.1    Solini, A.2
  • 5
    • 84901455931 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial
    • 5 Häring, H.-U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
    • (2014) Diabetes Care , vol.37 , pp. 1650-1659
    • Häring, H.-U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 6
    • 84885952950 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial
    • 6 Häring, H.-U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 36 (2013), 3396–3404.
    • (2013) Diabetes Care , vol.36 , pp. 3396-3404
    • Häring, H.-U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 7
    • 84892477577 scopus 로고    scopus 로고
    • Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
    • 7 Kovacs, C.S., Seshiah, V., Swallow, R., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2013), 147–158.
    • (2013) Diabetes Obes Metab , vol.16 , pp. 147-158
    • Kovacs, C.S.1    Seshiah, V.2    Swallow, R.3
  • 8
    • 84885954870 scopus 로고    scopus 로고
    • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
    • 8 Roden, M., Weng, J., Eilbracht, J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1 (2013), 208–219.
    • (2013) Lancet Diabetes Endocrinol , vol.1 , pp. 208-219
    • Roden, M.1    Weng, J.2    Eilbracht, J.3
  • 9
    • 83655193529 scopus 로고    scopus 로고
    • The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
    • 9 DeFronzo, R.A., Davidson, J.A., Del, P.S., The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14 (2012), 5–14.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 5-14
    • DeFronzo, R.A.1    Davidson, J.A.2    Del, P.S.3
  • 10
    • 84898854471 scopus 로고    scopus 로고
    • Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis
    • 10 Baker, W.L., Smyth, L.R., Riche, D.M., et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8 (2014), 262–275.
    • (2014) J Am Soc Hypertens , vol.8 , pp. 262-275
    • Baker, W.L.1    Smyth, L.R.2    Riche, D.M.3
  • 11
    • 84945455839 scopus 로고    scopus 로고
    • Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
    • 11 Chilton, R., Tikkanen, I., Cannon, C.P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 1180-1193
    • Chilton, R.1    Tikkanen, I.2    Cannon, C.P.3
  • 12
    • 84893214045 scopus 로고    scopus 로고
    • Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
    • 12 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circ 129 (2014), 587–597.
    • (2014) Circ , vol.129 , pp. 587-597
    • Cherney, D.Z.1    Perkins, B.A.2    Soleymanlou, N.3
  • 13
    • 16544362377 scopus 로고    scopus 로고
    • World Health Organization equations have shortcomings for predicting resting energy expenditure in persons from a modern, affluent population: generation of a new reference standard from a retrospective analysis of a German database of resting energy expenditure
    • 13 Muller, M.J., Bosy-Westphal, A., Klaus, S., et al. World Health Organization equations have shortcomings for predicting resting energy expenditure in persons from a modern, affluent population: generation of a new reference standard from a retrospective analysis of a German database of resting energy expenditure. Am J Clin Nutr 80 (2004), 1379–1390.
    • (2004) Am J Clin Nutr , vol.80 , pp. 1379-1390
    • Muller, M.J.1    Bosy-Westphal, A.2    Klaus, S.3
  • 14
    • 84939966139 scopus 로고    scopus 로고
    • Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study
    • 14 Heise, T., Mattheus, M., Woerle, H.J., et al. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Clin Ther 37 (2015), 793–803.
    • (2015) Clin Ther , vol.37 , pp. 793-803
    • Heise, T.1    Mattheus, M.2    Woerle, H.J.3
  • 15
    • 84899961819 scopus 로고    scopus 로고
    • Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
    • 15 Barnett, A.H., Mithal, A., Manassie, J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 369-384
    • Barnett, A.H.1    Mithal, A.2    Manassie, J.3
  • 16
    • 84908332537 scopus 로고    scopus 로고
    • Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
    • 16 Ridderstrale, M., Andersen, K.R., Zeller, C., et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 691-700
    • Ridderstrale, M.1    Andersen, K.R.2    Zeller, C.3
  • 17
    • 84903511385 scopus 로고    scopus 로고
    • Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes
    • 17 Rosenstock, J., Jelaska, A., Frappin, G., et al. Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes. Diabetes Care 37 (2014), 1815–1823.
    • (2014) Diabetes Care , vol.37 , pp. 1815-1823
    • Rosenstock, J.1    Jelaska, A.2    Frappin, G.3
  • 18
    • 84928196614 scopus 로고    scopus 로고
    • Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
    • 18 Tikkanen, I., Narko, K., Zeller, C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 33 (2014), 420–428.
    • (2014) Diabetes Care , vol.33 , pp. 420-428
    • Tikkanen, I.1    Narko, K.2    Zeller, C.3
  • 19
    • 84979895487 scopus 로고    scopus 로고
    • Empagliflozin and progression of kidney disease in type 2 diabetes
    • 19 Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
    • (2016) N Engl J Med , vol.375 , pp. 323-334
    • Wanner, C.1    Inzucchi, S.E.2    Lachin, J.M.3
  • 20
    • 84933523949 scopus 로고    scopus 로고
    • Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
    • 20 Skrtic, M., Yang, G.K., Perkins, B.A., et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetol 57 (2014), 2599–2602.
    • (2014) Diabetol , vol.57 , pp. 2599-2602
    • Skrtic, M.1    Yang, G.K.2    Perkins, B.A.3
  • 21
    • 84920971105 scopus 로고    scopus 로고
    • Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
    • 21 Lytvyn, Y., Škrtić, M., Yang, G.K., et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308 (2015), F77–83.
    • (2015) Am J Physiol Renal Physiol , vol.308 , pp. F77-83
    • Lytvyn, Y.1    Škrtić, M.2    Yang, G.K.3
  • 22
    • 84908555003 scopus 로고    scopus 로고
    • SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
    • 22 Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014;35:391–404.
    • (2014) Biopharm Drug Dispos , vol.35 , pp. 391-404
    • Chino, Y.1    Samukawa, Y.2    Sakai, S.3
  • 23
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • 23 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 24
    • 84874644599 scopus 로고    scopus 로고
    • KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
    • 24 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 3:Suppl (2013), 1–150.
    • (2013) Kidney Int , vol.3 , pp. 1-150
  • 25
    • 84980396108 scopus 로고    scopus 로고
    • 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
    • 25 Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 2129–2200.
    • (2016) Eur Heart J , vol.37 , pp. 2129-2200
    • Ponikowski, P.1    Voors, A.A.2    Anker, S.D.3
  • 26
    • 84951906012 scopus 로고    scopus 로고
    • Energy balance following sodium-glucose co-transporter-2 inhibition
    • 26 Ferrannini, G., Hach, T., Crowe, S., et al. Energy balance following sodium-glucose co-transporter-2 inhibition. Diabetes Care 38 (2015), 1730–1735.
    • (2015) Diabetes Care , vol.38 , pp. 1730-1735
    • Ferrannini, G.1    Hach, T.2    Crowe, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.